David Liebeskind, MD
Neurology · Los Angeles, CANPI 1629093091
Payments from drug & device makers
Across 353 payments — averaging $7720.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$1.1M
- Amgen$623K
- Stryker$588K
- Genentech, Inc.$171K
- Siemens Medical Solutions USA, Inc.$148K
- AstraZeneca$40K
- plus $70K from 17 others
Across 65 payments — averaging $22,248 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stryker$631K
- Route 92 Medical, Inc.$334K
- Genentech, Inc.$292K
- Medtronic$163K
- Neurovasc Technologies, Inc.$15K
- ZOLL Circulation Inc$9K
- plus $2K from 1 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 160 | $1,085,594 |
| Amgen | 8 | $623,212 |
| Stryker | 43 | $587,655 |
| Genentech, Inc. | 25 | $170,646 |
| Siemens Medical Solutions USA, Inc. | 4 | $148,236 |
| AstraZeneca | 36 | $40,252 |
| Silk Road Medical, Inc. | 13 | $24,750 |
| Medtronic(3 entities) | 26 | $11,426 |
| Astrazeneca UK Limited | 4 | $8,085 |
| Penumbra, Inc. | 4 | $6,372 |
| Shionogi Inc | 3 | $4,230 |
| Argenx US, Inc. | 1 | $3,450 |
| AbbVie | 2 | $3,025 |
| Balt USA, LLC | 2 | $2,544 |
| MIVI Neuroscience, Inc. | 5 | $2,167 |
| F. Hoffmann-la Roche AG | 4 | $1,767 |
| Olea Medical | 2 | $762 |
| Hyperfine Operations, Inc. | 1 | $600 |
| Phenox Inc. | 3 | $207 |
| Astrazeneca AB | 4 | $153 |
| Rapid Medical Ltd | 1 | $122 |
| Johnson & Johnson | 1 | $30 |
| EMD Serono Research & Development Institute, Inc. | 1 | $28 |
How this compares
$2,725,311 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Los Angeles
- Timothy CloughesyLos Angeles$33.1M
- Perry ShiehLos Angeles$8.2M
- Jeffrey SaverLos Angeles$2.9M
- David PiccioniLos Angeles$2.9M
- Michele TagliatiLos Angeles$2.5M
- Jennifer HuiLos Angeles$2.4M
- Susan PerlmanLos Angeles$2.2M
- Jeffrey CummingsLos Angeles$2M
- Bryan SpannLos Angeles$1.8M
- Lilyana AmezcuaLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.